Wednesday - January 8, 2025
WASHINGTON, Aug. 26, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) will host a live video webcast of its Diagnostics Investor and Analyst Meeting in Washington, D.C. on September 5, 2024 beginning at approximately 10:00 a.m. ET. The event will be hosted by Julie Sawyer Montgomery, Executive Vice President, Diagnostics. A link to the webcast and accompanying slide presentation will be available on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the video webcast will be available following the presentation.
ABOUT DANAHER
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at www.danaher.com.
Last Trade: | US$236.60 |
Daily Change: | -2.50 -1.05 |
Daily Volume: | 127,633 |
Market Cap: | US$170.890B |
January 06, 2025 November 26, 2024 October 22, 2024 September 17, 2024 July 23, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load